検索
Ascentage Pharma Group International
AAPGウォッチリストに追加
18.050USD
+0.090+0.50%
取引時間 （ET）15分遅れの株価
6.74B時価総額
--直近12ヶ月PER
詳細情報 Ascentage Pharma Group International 企業名
Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.
Ascentage Pharma Group Internationalの企業情報
企業コードAAPG
会社名Ascentage Pharma Group International
上場日Oct 28, 2019
最高経営責任者「CEO」Yang (Dajun)
従業員数- -
証券種類Depository Receipt
決算期末- -
本社所在地68 Xinqing Road, Suzhou Industrial Park
都市SUZHOU
証券取引所NASDAQ OMX - NASDAQ BASIC
国China
郵便番号- -
電話番号
ウェブサイトhttps://www.ascentage.cn/
企業コードAAPG
上場日Oct 28, 2019
最高経営責任者「CEO」Yang (Dajun)
Ascentage Pharma Group Internationalの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Dajun Yang, M.D., Ph.D.
Dr. Dajun Yang, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Shaomeng Wang, Ph.D.
Dr. Shaomeng Wang, Ph.D.
Non-Executive Director, Co-Founder
Non-Executive Director, Co-Founder
--
--
Dr. Dazhong (Simon) Lu, Ph.D.
Dr. Dazhong (Simon) Lu, Ph.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Wei Ren
Mr. Wei Ren
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. Yifan Zhai, M.D., Ph.D.
Dr. Yifan Zhai, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Raymond Jeffrey (Jeff) Kmetz
Mr. Raymond Jeffrey (Jeff) Kmetz
Chief Business Officer
Chief Business Officer
--
--
Mr. Thomas Joseph (Tom) Knapp, J.D.
Mr. Thomas Joseph (Tom) Knapp, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Ms. Marina S. Bozilenko
Ms. Marina S. Bozilenko
Independent Non-Executive Director
Independent Non-Executive Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Dajun Yang, M.D., Ph.D.
Dr. Dajun Yang, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Shaomeng Wang, Ph.D.
Dr. Shaomeng Wang, Ph.D.
Non-Executive Director, Co-Founder
Non-Executive Director, Co-Founder
--
--
Dr. Dazhong (Simon) Lu, Ph.D.
Dr. Dazhong (Simon) Lu, Ph.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Wei Ren
Mr. Wei Ren
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
よくある質問
Ascentage Pharma Group Internationalの上位5名の株主は誰ですか？
Ascentage Pharma Group Internationalの上位5名の株主は以下のとおりです。Dr. Dajun Yang, M.D., Ph.D.
Ascentage Pharma Group International（AAPG）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Ascentage Pharma Group Internationalの株式を保有している機関は25社あり、保有株式の総市場価値は約65.84Kで、全体の0.07%を占めています。2025Q4と比較して、機関の持ち株は-220958.00増加しています。